ArticleAdvances in therapy2026
Diagnostic Delay in Multiple Sclerosis in China: A Nationwide Cross-Sectional Study.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionMultiple sclerosis (MS) is a rare disease in China. Evidence on the extent and contributing factors of diagnostic delay in China remains limited. This study aimed to assess the proportion and duration of diagnostic delay in MS and to identify associated factors in the Chinese context.
methodsIn July 2022, we conducted a nationwide cross-sectional survey in collaboration with a major Chinese MS patient network. A random sample of adults (≥ 18 years) with a clinically confirmed MS diagnosis was recruited through online patient support groups. Diagnostic delays were defined as the time between symptom onset and a confirmed MS diagnosis, with delays exceeding 3 months classified as "delayed". Delay was further classified into pre-first-consultation and post-first-consultation intervals. Multivariable logistic regression and sensitivity analyses were used to assess associations between diagnostic delay and sociodemographic, clinical, and health system-related factors.
resultsAmong the 722 participants (mean (SD) age 34.62 (9.86) years; 488 women (67.60%), 48.48% experienced a diagnostic delay longer than 3 months. The mean (SD) time from symptom onset to diagnosis was 16.23 (35.33) months (median 3.0 months), with the majority (mean (SD) 11.27 (27.83) months; median 1.0 month) of delays occurring after the first clinical consultation. Higher health literacy (odds ratio (OR) 0.41; 95% CI 0.20-0.84), initial consultation in a neurology/neurosurgery department (OR 0.19; 95% CI 0.12-0.29), and symptom onset in/after 2018 (OR 0.49; 95% CI 0.32-0.75) were associated with lower odds of diagnostic delay. Sensitivity analyses using 2-month and 5-month thresholds confirmed the robustness of these findings.
conclusionsMS diagnostic delays are common in China, driven by low health literacy and suboptimal healthcare pathways. Efforts to improve public awareness, implement structured referral systems, and enhance diagnostic capacity are urgently needed. These insights may inform strategies for reducing diagnostic delays in developing countries and improving outcomes for patients with MS.
Indexed as
Identifiers
42334797What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.